SlideShare une entreprise Scribd logo
1  sur  9
The Truth  About the Drug Companies  Marcia Angell, M.D.
WORLD’S TOP 10 DRUG COMPANIES  AND PRESCRIPTION DRUG SALES 2008 Total:  5  American,  5  European,  $310 billion Source:  IMS Health “Top 15 Global Corporations”  www.IMSHealth.com, accessed   8/27/09
*FORTUNE 500 U.S. DRUG COMPANIES 2008 SALES AND EXPENSES Billions Average drug company profits 18% v. 0.9% for all Fortune 500 industries *Johnson&Johnson, Pfizer, Abbott, Merck, Wyeth, Bristol-Myers Squibb, Lilly, Schering-Plough, Amgen, Gilead Sciences Source:  Fortune  5/4/09; company annual reports (31%) (15%) (18%)
New Drug Approvals 2000-2007 (8 years) 667 new drug approvals Only 75 (11%) were both NME’s and improvements
Innovation: Published Research Leading to Drugs Sources:  Internal NIH document available from Public Citizen;  also Zinner, Health Affairs, Sept-Oct 2001; also Boston Globe 4/5/98
$55 BILLION Source of picture:  Cover of  An Elephant in The Living Room: The Children’s Book by Jill M. Hastings, M.S. and Marion H. Typpo, Ph.D.
What’s The Elephant Up To? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Patients pay 20%  mark-up on drug prices.
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The Pharmaceutical Industry  and Health Reform ,[object Object],[object Object],[object Object],[object Object],[object Object]

Contenu connexe

Tendances

Brian Ager - Selling Sickness 2010
Brian Ager - Selling Sickness 2010Brian Ager - Selling Sickness 2010
Brian Ager - Selling Sickness 2010
Gezonde scepsis
 
Health technology assessment
Health technology assessmentHealth technology assessment
Health technology assessment
pranaliparab
 
7 Moynihan Drug promotion
7 Moynihan Drug promotion7 Moynihan Drug promotion
7 Moynihan Drug promotion
Gordon Renouf
 
Direct-to-Consumer Advertising in the Digital Age
Direct-to-Consumer Advertising in the Digital AgeDirect-to-Consumer Advertising in the Digital Age
Direct-to-Consumer Advertising in the Digital Age
sggibson
 
Ray Moynihan- Selling Sickness Amsterdam
Ray Moynihan- Selling Sickness AmsterdamRay Moynihan- Selling Sickness Amsterdam
Ray Moynihan- Selling Sickness Amsterdam
Gezonde scepsis
 
Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan
Anup Soans
 
Direct To Consumer Drug Advertising
Direct To Consumer Drug AdvertisingDirect To Consumer Drug Advertising
Direct To Consumer Drug Advertising
guest78c907
 
15 Billion Secret
15 Billion Secret15 Billion Secret
15 Billion Secret
smithcjs
 
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical IndustryDirect To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
jinender16
 

Tendances (20)

Big pharma nardi
Big pharma nardiBig pharma nardi
Big pharma nardi
 
Brian Ager - Selling Sickness 2010
Brian Ager - Selling Sickness 2010Brian Ager - Selling Sickness 2010
Brian Ager - Selling Sickness 2010
 
Health technology assessment
Health technology assessmentHealth technology assessment
Health technology assessment
 
7 Moynihan Drug promotion
7 Moynihan Drug promotion7 Moynihan Drug promotion
7 Moynihan Drug promotion
 
Direct-to-Consumer Advertising in the Digital Age
Direct-to-Consumer Advertising in the Digital AgeDirect-to-Consumer Advertising in the Digital Age
Direct-to-Consumer Advertising in the Digital Age
 
Cb jan08
Cb jan08Cb jan08
Cb jan08
 
Ray Moynihan- Selling Sickness Amsterdam
Ray Moynihan- Selling Sickness AmsterdamRay Moynihan- Selling Sickness Amsterdam
Ray Moynihan- Selling Sickness Amsterdam
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for Everyone
 
Drug advertising for presentation
Drug advertising for presentationDrug advertising for presentation
Drug advertising for presentation
 
Claire Hulme
Claire HulmeClaire Hulme
Claire Hulme
 
Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan
 
Direct To Consumer Drug Advertising
Direct To Consumer Drug AdvertisingDirect To Consumer Drug Advertising
Direct To Consumer Drug Advertising
 
15 Billion Secret
15 Billion Secret15 Billion Secret
15 Billion Secret
 
High Cost of Prescription Drugs - What can we do about it?
High Cost of Prescription Drugs - What can we do about it?High Cost of Prescription Drugs - What can we do about it?
High Cost of Prescription Drugs - What can we do about it?
 
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical IndustryDirect To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
 
Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019Prescription Medicines - Costs In Context March 2019
Prescription Medicines - Costs In Context March 2019
 
BIL 2009 Personalized Medicine And Personal Genomics
BIL 2009 Personalized Medicine And Personal GenomicsBIL 2009 Personalized Medicine And Personal Genomics
BIL 2009 Personalized Medicine And Personal Genomics
 
Is European market access becoming an incubator for rare disease development?...
Is European market access becoming an incubator for rare disease development?...Is European market access becoming an incubator for rare disease development?...
Is European market access becoming an incubator for rare disease development?...
 
Infographic: Access to OTC Medicines
Infographic: Access to OTC MedicinesInfographic: Access to OTC Medicines
Infographic: Access to OTC Medicines
 
Joghnson
JoghnsonJoghnson
Joghnson
 

Similaire à The Truth About The Drug Companies Marcia Angell

Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
MedicineAndHealthUSA
 
Scenario and Strategic Planning: A Case Study of Eli Lily & Co.
Scenario and Strategic Planning: A Case Study of Eli Lily & Co.Scenario and Strategic Planning: A Case Study of Eli Lily & Co.
Scenario and Strategic Planning: A Case Study of Eli Lily & Co.
Yee Jie NG
 
Bioinformatix' Rx&You: Enterprise Intelligence for Medications
Bioinformatix' Rx&You:  Enterprise Intelligence for MedicationsBioinformatix' Rx&You:  Enterprise Intelligence for Medications
Bioinformatix' Rx&You: Enterprise Intelligence for Medications
Bioinformatix LLC
 
Conflict of interest week 3 written assignment mha
Conflict of interest week 3 written assignment mhaConflict of interest week 3 written assignment mha
Conflict of interest week 3 written assignment mha
shendrix489
 
2013 màster upf josep m. badenas
2013 màster upf josep m. badenas2013 màster upf josep m. badenas
2013 màster upf josep m. badenas
Josep-Maria Badenas
 

Similaire à The Truth About The Drug Companies Marcia Angell (20)

Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
 
Universal Health Coverage
Universal Health CoverageUniversal Health Coverage
Universal Health Coverage
 
Scenario and Strategic Planning: A Case Study of Eli Lily & Co.
Scenario and Strategic Planning: A Case Study of Eli Lily & Co.Scenario and Strategic Planning: A Case Study of Eli Lily & Co.
Scenario and Strategic Planning: A Case Study of Eli Lily & Co.
 
Generics and the Animal Health Industry
Generics and the Animal Health IndustryGenerics and the Animal Health Industry
Generics and the Animal Health Industry
 
Science As A Business
Science As A BusinessScience As A Business
Science As A Business
 
Bioinformatix' Rx&You: Enterprise Intelligence for Medications
Bioinformatix' Rx&You:  Enterprise Intelligence for MedicationsBioinformatix' Rx&You:  Enterprise Intelligence for Medications
Bioinformatix' Rx&You: Enterprise Intelligence for Medications
 
Conflict of interest week 3 written assignment mha
Conflict of interest week 3 written assignment mhaConflict of interest week 3 written assignment mha
Conflict of interest week 3 written assignment mha
 
The Economics of Quality in Healthcare
The Economics of Quality in HealthcareThe Economics of Quality in Healthcare
The Economics of Quality in Healthcare
 
13. 2015 mwan 010815 testimony to federal election commission 1 8-15
13.  2015 mwan 010815  testimony to federal election commission  1 8-1513.  2015 mwan 010815  testimony to federal election commission  1 8-15
13. 2015 mwan 010815 testimony to federal election commission 1 8-15
 
Ethics in pharma industry
Ethics in pharma industryEthics in pharma industry
Ethics in pharma industry
 
BioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of BiotechBioEntrepreneurship: The Business of Biotech
BioEntrepreneurship: The Business of Biotech
 
Final
FinalFinal
Final
 
2013 màster upf josep m. badenas
2013 màster upf josep m. badenas2013 màster upf josep m. badenas
2013 màster upf josep m. badenas
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
The truth behind herbal supplements on social media
The truth behind herbal supplements on social mediaThe truth behind herbal supplements on social media
The truth behind herbal supplements on social media
 
The Orphan Drug Act
The Orphan Drug ActThe Orphan Drug Act
The Orphan Drug Act
 
Obama care a new opportunity in us healthcare - finpro
Obama care   a new opportunity in us healthcare - finproObama care   a new opportunity in us healthcare - finpro
Obama care a new opportunity in us healthcare - finpro
 
Changing the Medical Research Paradigm
Changing the Medical Research ParadigmChanging the Medical Research Paradigm
Changing the Medical Research Paradigm
 
Universalhealthcarelecture2
Universalhealthcarelecture2Universalhealthcarelecture2
Universalhealthcarelecture2
 
MEDICAL ETHICS AND CONFLICT OF INTEREST IN SCIENTIFIC MEDICINE
MEDICAL ETHICS AND CONFLICT OF INTEREST IN SCIENTIFIC MEDICINEMEDICAL ETHICS AND CONFLICT OF INTEREST IN SCIENTIFIC MEDICINE
MEDICAL ETHICS AND CONFLICT OF INTEREST IN SCIENTIFIC MEDICINE
 

The Truth About The Drug Companies Marcia Angell

  • 1. The Truth About the Drug Companies Marcia Angell, M.D.
  • 2. WORLD’S TOP 10 DRUG COMPANIES AND PRESCRIPTION DRUG SALES 2008 Total: 5 American, 5 European, $310 billion Source: IMS Health “Top 15 Global Corporations” www.IMSHealth.com, accessed 8/27/09
  • 3. *FORTUNE 500 U.S. DRUG COMPANIES 2008 SALES AND EXPENSES Billions Average drug company profits 18% v. 0.9% for all Fortune 500 industries *Johnson&Johnson, Pfizer, Abbott, Merck, Wyeth, Bristol-Myers Squibb, Lilly, Schering-Plough, Amgen, Gilead Sciences Source: Fortune 5/4/09; company annual reports (31%) (15%) (18%)
  • 4. New Drug Approvals 2000-2007 (8 years) 667 new drug approvals Only 75 (11%) were both NME’s and improvements
  • 5. Innovation: Published Research Leading to Drugs Sources: Internal NIH document available from Public Citizen; also Zinner, Health Affairs, Sept-Oct 2001; also Boston Globe 4/5/98
  • 6. $55 BILLION Source of picture: Cover of An Elephant in The Living Room: The Children’s Book by Jill M. Hastings, M.S. and Marion H. Typpo, Ph.D.
  • 7.
  • 8.
  • 9.

Notes de l'éditeur

  1. *Pfizer, Johnson&Johnson, Abbott, Merck, Bristol-Myers Squibb, Wyeth, Lilly, Amgen, Schering-Plough